tradingkey.logo
tradingkey.logo
Search

OptimizeRx Corp

OPRX
Add to Watchlist
6.190USD
+0.110+1.81%
Close 07/02, 13:00ETQuotes delayed by 15 min
116.16MMarket Cap
16.76P/E TTM

More Details of OptimizeRx Corp Company

OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers.

OptimizeRx Corp Info

Ticker SymbolOPRX
Company nameOptimizeRx Corp
IPO dateMay 18, 2005
CEOSilvestro (Stephen L)
Number of employees106
Security typeOrdinary Share
Fiscal year-endMay 18
Address260 Charles Street
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02453
Phone12486516558
Websitehttps://www.optimizerx.com/
Ticker SymbolOPRX
IPO dateMay 18, 2005
CEOSilvestro (Stephen L)

Company Executives of OptimizeRx Corp

Name
Name/Position
Position
Shareholding
Change
Mr. James (Jim) Lang
Mr. James (Jim) Lang
Independent Director
Independent Director
423.97K
+8.14%
Mr. Stephen L. (Steve) Silvestro
Mr. Stephen L. (Steve) Silvestro
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
106.51K
-4.90%
Mr. Gregory D. (Greg) Wasson
Mr. Gregory D. (Greg) Wasson
Independent Director
Independent Director
81.83K
+42.18%
Mr. Edward (Ed) Stelmakh
Mr. Edward (Ed) Stelmakh
Chief Financial & Strategic Officer
Chief Financial & Strategic Officer
72.86K
-2.50%
Mr. Patrick D. (Pat) Spangler
Mr. Patrick D. (Pat) Spangler
Independent Director
Independent Director
68.86K
+50.12%
Mr. Doug Besch
Mr. Doug Besch
Chief Product Officer and Chief Technology Officer
Chief Product Officer and Chief Technology Officer
66.88K
-4.03%
Ms. Catherine M. Klema
Ms. Catherine M. Klema
Independent Director
Independent Director
46.27K
+74.60%
Mr. Andy D'Silva
Mr. Andy D'Silva
Chief Business Officer
Chief Business Officer
44.73K
-3.51%
Ms. Theresa Greco
Ms. Theresa Greco
Chief Commercial Officer
Chief Commercial Officer
32.73K
-5.48%
Ms. Lynn O'Connor Vos
Ms. Lynn O'Connor Vos
Independent Chairperson of the Board
Independent Chairperson of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. James (Jim) Lang
Mr. James (Jim) Lang
Independent Director
Independent Director
423.97K
+8.14%
Mr. Stephen L. (Steve) Silvestro
Mr. Stephen L. (Steve) Silvestro
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
106.51K
-4.90%
Mr. Gregory D. (Greg) Wasson
Mr. Gregory D. (Greg) Wasson
Independent Director
Independent Director
81.83K
+42.18%
Mr. Edward (Ed) Stelmakh
Mr. Edward (Ed) Stelmakh
Chief Financial & Strategic Officer
Chief Financial & Strategic Officer
72.86K
-2.50%
Mr. Patrick D. (Pat) Spangler
Mr. Patrick D. (Pat) Spangler
Independent Director
Independent Director
68.86K
+50.12%
Mr. Doug Besch
Mr. Doug Besch
Chief Product Officer and Chief Technology Officer
Chief Product Officer and Chief Technology Officer
66.88K
-4.03%

FAQs

Who are the top five shareholders of OptimizeRx Corp?

The top five shareholders of OptimizeRx Corp are: Mr. James (Jim) Lang

How many institutions hold shares of OptimizeRx Corp (OPRX)?

As of 2026Q1, 300 institutions hold shares of OptimizeRx Corp, with a combined market value of approximately 15.47M, accounting for 82.46% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -5161941.00.